SKYE (Skye Bioscience Inc.) stock: $0.99, $4.4M market cap, $8.1M cash, -$3.7M EV, $48.4M fully diluted market cap. Next expected readout: Nov-26. Lead program: Nimacimab injection (Obesity), Phase 2. Data from Fully Diluted's biotech stocks database.
Pending acquisition: Skye is acquiring Redx Pharma. Figures on this page are Skye standalone, before the deal.
What they do
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
35.4M
Pre-funded warrants
4.6M
Options
5.2M
RSUs
0.5M
Warrants
3.1M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.2M
FDSO
48.9M
Cap table as of 2026-06-30.
Definitive agreement announced August 12, 2026 for Skye to acquire Redx Pharma by a UK scheme of arrangement. At the deal's own marks (Skye valued at $14.5M against Redx at $125M, plus a $36M Redx Series A and a concurrent financing), existing Skye holders would own roughly 8% of the combined company. The share counts and cash on this page are Skye standalone and will be replaced at closing. A pro forma share count has not been disclosed yet; the deal still needs Skye stockholder approval, including a reverse split vote.
Partnerships n/a (Halozyme ENHANZE license: termination notice sent August 11, 2026)
Indications
Obesity and overweight(Phase 2)
Status note CBeyond Phase 2a completed; an IV expansion study (Part C) was initiated in March 2026. In Q2 2026 management terminated the CBeyond trial and paused all associated R&D activities for nimacimab; company is pursuing the proposed acquisition of Redx Pharma (agreement signed August 14, 2026).
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.